Skip to main content
    F

    Foghorn Therapeutics Inc (FHTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.79
    -0.28 (-13.53%)

    Market Cap: $124.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Foghorn Therapeutics Inc (FHTX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Foghorn Therapeutics (FHTX) is expected to report earnings on Mar 9, 2027. In the quarter ended Sep 30, 2026, Foghorn Therapeutics reported EPS of $0.80, above the -$0.23 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(10/26)
    Avg Surprise
    +3.61%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.25
    Range-$0.32 - -$0.17
    11 analysts
    Revenue Consensus
    $2.24M
    RangeN/A
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.23
    Range-$0.26 - -$0.18
    3 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.27+13.8%
    60d ago-$0.27+13.8%
    30d ago-$0.24+4.2%
    7d ago-$0.24+4.2%
    Current-$0.23
    Revenue Consensus
    $12.50M
    Range$12.50M - $12.50M
    1 analysts

    Next Report

    FHTX has an expected report date of Mar 9, 2027.

    Earnings History

    Of the 26 quarters below that had an estimate, FHTX beat 10, missed 15 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $83.54M, up 925.0% from $8.15M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.80-$0.23-$0.41 - -$0.15+447.83%BeatN/A70 up, 2 downNov 9, 2026$83.54M
    Jun 30, 2026-$0.10-$0.23-$0.32 - -$0.14+56.52%BeatN/A71 up, 0 downAug 6, 2026$16.07M
    Mar 31, 2026-$0.29-$0.31-$0.38 - -$0.27+6.45%BeatN/A40 up, 1 downMay 7, 2026$3.27M
    Dec 31, 2025-$0.37-$0.26-$0.37 - -$0.16-41.14%MissN/A91 up, 0 downMar 11, 2026$9.25M
    Sep 30, 2025-$0.25-$0.31-$0.40 - -$0.22+19.35%BeatN/A61 up, 0 downNov 5, 2025$8.15M
    Jun 30, 2025-$0.28-$0.32-$0.40 - -$0.21+12.50%BeatN/A60 up, 3 downAug 5, 2025$7.56M
    Mar 31, 2025-$0.30-$0.29-$0.34 - -$0.24-3.45%MissN/A40 up, 0 downMay 14, 2025$5.95M
    Dec 31, 2024-$0.30-$0.28-$0.37 - -$0.23-7.14%MissN/A41 up, 0 downMar 6, 2025$2.86M
    Sep 30, 2024-$0.31-$0.43-$0.56 - -$0.35+27.91%BeatN/A50 up, 0 downNov 4, 2024$7.81M
    Jun 30, 2024-$0.45-$0.64-$0.82 - -$0.52+29.69%BeatN/A40 up, 0 downAug 8, 2024$6.89M
    Mar 31, 2024-$0.59-$0.59-$0.87 - -$0.510.00%In lineN/A40 up, 0 downMay 6, 2024$5.05M
    Dec 31, 2023-$0.57-$0.76-$0.94 - -$0.63+25.00%BeatN/A50 up, 0 downMar 7, 2024$5.77M
    Sep 30, 2023-$0.34-$0.65N/A+47.69%BeatN/A41 up, 0 downNov 2, 2023$17.48M
    Jun 30, 2023-$0.70-$0.69-$0.78 - -$0.66-1.45%MissN/A40 up, 0 downAug 4, 2023$5.60M
    Mar 31, 2023-$0.73-$0.72-$0.86 - -$0.66-1.39%MissN/A40 up, 0 downMay 8, 2023$5.31M
    Dec 31, 2022-$0.69-$0.54-$0.81 - -$0.33-27.78%MissN/A50 up, 0 downMar 9, 2023$4.18M
    Sep 30, 2022-$0.62-$0.50-$0.70 - -$0.42-24.00%MissN/A40 up, 0 downNov 8, 2022$6.63M
    Jun 30, 2022-$0.66-$0.41-$0.78 - -$0.33-60.98%MissN/A40 up, 0 downAug 9, 2022$4.49M
    Mar 31, 2022-$0.65-$0.47-$0.81 - -$0.27-38.30%MissN/A40 up, 0 downMay 9, 2022$3.92M
    Dec 31, 2021-$0.74-$0.49-$0.78 - $0.50-51.02%MissN/A50 up, 0 downMar 10, 2022$713000
    Sep 30, 2021-$0.71-$0.59N/A-20.34%MissN/A3N/ANov 9, 2021$41000
    Jun 30, 2021-$0.63-$0.59N/A-6.78%MissN/A3N/AAug 10, 2021$279000
    Mar 31, 2021-$0.62-$0.55N/A-12.73%MissN/A3N/AMay 11, 2021$286000
    Dec 31, 2020-$1.86-$0.45-$0.70 - $0.06-313.33%MissN/A4N/AMar 18, 2021$251000
    Sep 30, 2020-$3.12-$2.69-$3.06 - -$0.55-15.99%MissN/A3N/AOct 23, 2020$179000
    Jun 30, 2020-$1.29-$2.42N/A+46.69%BeatN/AN/AN/ASep 2, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.20, after -$1.65 the year before. It was -$6.27 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.20N/A
    Dec 31, 2024-$1.65N/A
    Dec 31, 2023-$2.34N/A
    Dec 31, 2022-$2.62N/A
    Dec 31, 2021-$2.70N/A
    Dec 31, 2020-$6.27N/A

    Frequently Asked Questions About FHTX

    When is Foghorn Therapeutics's next earnings date?

    Foghorn Therapeutics's next earnings report is expected for Mar 9, 2027.

    Did FHTX beat earnings estimates last quarter?

    Yes. Foghorn Therapeutics reported EPS of $0.80 for the quarter ended Sep 30, 2026, above the -$0.23 estimate, a 447.83% surprise.

    What EPS do analysts expect from FHTX next quarter?

    The consensus EPS estimate for Foghorn Therapeutics for the quarter ending Dec 31, 2026 is -$0.25 from 11 analysts, with estimates from -$0.32 to -$0.17.

    How often does FHTX beat earnings estimates?

    Foghorn Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +61.37%.